ENDV.US Endonovo Therapeutics Inc
- Market cap
- USD 181K
- P/E
- 0.0x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ENDV.US undervalued?
Graham numberThe Graham number of Endonovo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Endonovo Therapeutics Inc fundamental analysis
No fundamental analysis for Endonovo Therapeutics Inc yet.
Endonovo Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver d…
Full company profileEndonovo Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Endonovo Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 83.3K | 310K | 166K | 73.1K | 135K | 140K | 10.0K | - | - |
| Gross Profit | -15.8K | -14.8K | 70.3K | 217K | 100K | 58.1K | 125K | -515K | -615K | - | - |
| Operating Income | -5.41M | -4.60M | -4.16M | -3.81M | -2.91M | -2.23M | -3.26M | -2.92M | -1.56M | -946K | -1.11M |
| EBITDA | -5.40M | -4.59M | -589K | -10.6M | 2.34M | -1.51M | -16.5M | 8.85M | -941K | -946K | -1.11M |
| Net Income | -5.32M | -10.8M | -6.44M | -17.3M | -396K | -3.10M | -18.5M | 6.92M | -2.80M | -2.18M | -2.35M |
| EPS | -45 | -33 | -18 | -25 | -0.03 | -0.05 | -0.13 | 0.01 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 319K | 4.61M | 4.24M | 3.27M | 2.61M | 2.01M | 1.28M | 640K | 19.3K | 19.3K | 44.8K |
| Total Liabilities | 8.88M | 14.2M | 15.6M | 23.8M | 17.0M | 17.8M | 33.5M | 24.7M | 26.8M | 28.9M | 30.1M |
| Shareholders' Equity | -8.56M | -9.55M | -11.4M | -20.5M | -14.4M | -15.8M | -32.2M | -24.1M | -26.8M | -28.9M | -30.0M |
| Cash & Short-term Investments | 55.5K | 90.2K | 379K | 18.9K | 13.4K | 85.9K | 98.00 | 1.84K | 3.00 | 12.00 | 25.6K |
| Total Debt | 2.06M | 4.74M | 6.32M | 6.86M | 6.63M | 7.18M | 7.15M | 7.07M | 6.87M | 6.91M | 7.04M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.46M | -2.99M | -2.88M | -2.54M | -742K | -987K | -679K | 122K | 100K | -43.0K | -199K |
| Capital Expenditure | 8.97K | 3.00M | 8.97K | 2.59K | 0.00 | 4.00 | 0.00 | 0.00 | 3.00 | 0.00 | 16.00 |
| Free Cash Flow | -2.46M | -5.99M | -2.89M | -2.54M | -742K | -987K | -679K | 122K | 100K | -43.0K | -199K |
| Ratios | |||||||||||
| ROA | -1,668.0% | -234.4% | -151.7% | -528.7% | -15.2% | -154.7% | -1,441.9% | 1,082.5% | -14,502.0% | -11,275.3% | -5,240.0% |
| Net Profit Margin | - | - | -7,729.5% | -5,582.4% | -238.6% | -4,247.2% | -13,649.2% | 4,937.6% | -27,853.2% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Endonovo Therapeutics Inc dividends
Endonovo Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1000 on Dec 20, 2019.
Who owns Endonovo Therapeutics Inc
Ownership data of Endonovo Therapeutics Inc is not available yet.
Endonovo Therapeutics Inc company profile
- Company name
- Endonovo Therapeutics Inc
- Ticker
- ENDV.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 6320 Canoga Avenue, Woodland Hills, CA, United States, 91367
- Phone
- 800 489 4774
- Website
- endonovo.com
About Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Endonovo Therapeutics Inc management
4- Mr. Alan Brian CollierChairman & CEO · born 1966
- Mr. Don CalabriaVice President of Operations
- Mr. Garry Michael KannHead of Corporate Development
- Mr. Ira WeisbergPresident & Chief Commercial Officer of Medical Division · born 1949